Aragen Life Sciences elevates Pavan Kumar Kamarajugadda to Senior Director

Aragen scales Renaissance Pharma’s cancer antibody to commercial GMP in just 9 months

Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru

Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab

CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes

Aragen appoints Neeraj Garg as CEO - Discovery Solutions business

In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base

Aragen secures $100 million investment from Quadria Capital

Investment will fund expansion to meet rising demand for CRDMO services

Aragen receives SBTi approval for its greenhouse gas emission reduction targets

Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval

Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule

Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India

Executes the first project for developing and manufacturing a novel anticancer mAb

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution